Events

Page of ( Articles)

Othocell confirms Australian reimbursement for CelGro March 4, 2021
Regenerative medicine company Orthocell (ASX:OCC) has announced it has received notification from the Australian Department of Health that its CelGro Dental has been included on the Prostheses List.
Kazia Therapeutics signs global agreement for lead candidate March 4, 2021
Emerging Australia oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced a license agreement for its lead pipeline candidate Cantrixil (TRX-E-002-1).
CSL: 'We have well over one million doses in the fridge' March 4, 2021
Senior representatives of CSL appeared earlier this week before the ongoing Senate inquiry into the federal government's response to the COVID-19 pandemic.
Mesoblast boosts cash through private placement March 4, 2021
Mesoblast (ASX:MSB) has raised US$110 million (A$138 million) via the issue of 60 million shares in a private placement led by a US investor group.
Research identifies cause and potential treatment for COVID-19-induced heart damage March 4, 2021
Researchers at the Brisbane-based QIMR Berghofer have discovered some of the ways COVID-19 damages the heart and identified a class of drugs that could potentially protect or reverse this injury.
AusMedtech 2021 programme launched March 4, 2021
An inspiring line-up of Australian and global keynotes and panels has been revealed as the AusMedtech 2021 conference programme is launched. 'AusMedtech 2021: Reimagine and reconnect' provides virtual half-day sessions across five days, 17 – 21 May, that represent Australia’s medtech industry.
Osprey expands US sales coverage with new sales agency agreements March 2, 2021
Osprey Medical (ASX:OSP) has signed Independent Sales Agency agreements with Access Medical, Consolidated Medical Supplies and DriKot Medical that will expand its sales coverage in the US.
Botanix expands its management team March 2, 2021
Australian clinical-stage synthetic cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced the expansion of its management team with the appointment of three executives in the US.
Funding for advances in medical research technology March 2, 2021
Health minister Greg Hunt has announced the federal government will invest $100 million in the development of new technologies to improve diagnosis and treatment of stroke, epilepsy and lung disease, including COVID-19.
Cynata Therapeutics announces new study of cell therapy March 2, 2021
Cynata Therapeutics (ASX:CYP), a clinical-stage biotechnology company specialising in cell therapeutics, has announced the initiation of a new study to investigate its Cymerus mesenchymal stem cells.
Funding opens for advanced bio-manufacturing March 2, 2021
AusBiotech welcomes the Government’s support of the biotech industry as it opens the first round of funding for bio-manufacturing and launches its Medical Products’ National Manufacturing Priority road map.
Opthea confirms plans and protocols for late-stage OPT-302 studies February 25, 2021
Opthea (ASX:OPT) says it has finalised the protocol study designs and key start-up activities in readiness for the initiation of the phase three ShORe and COAST pivotal clinical trials of OPT-302 in wet age-related macular degeneration.

Page of ( Articles)

Events

Most Read

Funding opens for advanced bio-manufacturing

Botanix expands its management team

Cynata Therapeutics announces new study of cell therapy

Funding for advances in medical research technology

Osprey expands US sales coverage with new sales agency agreements

New Stories

Othocell confirms Australian reimbursement for CelGro

Kazia Therapeutics signs global agreement for lead candidate

CSL: 'We have well over one million doses in the fridge'

Mesoblast boosts cash through private placement

Research identifies cause and potential treatment for COVID-19-induced heart damage

Osprey expands US sales coverage with new sales agency agreements

Botanix expands its management team

Sign In

Most Read

Funding opens for advanced bio-manufacturing

Botanix expands its management team

Cynata Therapeutics announces new study of cell therapy

Funding for advances in medical research technology

Osprey expands US sales coverage with new sales agency agreements

Follow Us

New Stories

Othocell confirms Australian reimbursement for CelGro

Kazia Therapeutics signs global agreement for lead candidate

CSL: 'We have well over one million doses in the fridge'

Mesoblast boosts cash through private placement

Research identifies cause and potential treatment for COVID-19-induced heart damage

Osprey expands US sales coverage with new sales agency agreements

Botanix expands its management team